Overview
Description
About
Suite 906
Los Angeles, 90067, CA
United States
Latest press releases
Equity Insider News Commentary
Issued on behalf of Avant Technologies Inc.
VANCOUVER, BC, July 29, 2025 /PRNewswire/ -- Equity Insider News Commentary – There's a lot of big voices pushing for the AI revolution to make its mark, including a new plan from the U.S. Department of Commerce to address slow-to-adopt sectors like healthcare. The comes as part of US President Trump's paper, titled Winning the Race: AMERICA'S AI ACTION PLAN, which encourages setting up regulatory sandboxes, or regulation-free environments where AI can be tested in real world scenarios with heavy oversight. As the market evaluates the opportunities available, several tech and biotech companies are already moving towards major milestones in AI-powered healthcare solutions, including Avant Technologies, Inc. (OTCQB: AVAI), Renovaro Inc. (NASDAQ: RENB), Healthcare Triangle, Inc. (NASDAQ: HCTI), GE HealthCare Technologies Inc. (NASDAQ: GEHC), and Spectral AI, Inc. (NASDAQ: MDAI).
According to Accenture, AI could inject an additional $461 billion into the healthcare sector by 2035, as it surpasses the $2.26 trillion mark. Now, as AI makes its move into the healthcare space, experts are working to help guide these new solutions towards being more accurate, in a space where AI's inaccuracies (known as "hallucinations") are not an option. Thankfully, there are several players making important advancements in diagnostics, drug development, and workflow, through the use of AI.
Avant Technologies, Inc. (OTCQB: AVAI) and joint-venture partner Ainnova Tech have taken a key regulatory step forward by finalizing an updated clinical trial protocol for their AI-powered Vision AI platform, following formal feedback from a mid-July pre-submission meeting with the FDA. The revised protocol, which addresses the FDA's comments, has now been presented to Fortrea, the company's contract research organization, for review. Once approved, the protocol will enable the launch of a new U.S.-based clinical trial designed to support Ainnova's goal of obtaining FDA 510(k) clearance for Vision AI in the early detection of diabetic retinopathy.
"We are committed to meeting the highest regulatory standards, and we're confident that these protocol refinements will strengthen our path toward FDA 510(k) clearance," said Vinicio Vargas, CEO at Ainnova and a member of the Board of Directors of Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova to advance and commercialize Ainnova's technology portfolio. "We anticipate finalizing the clinical trial budget soon, with estimated costs coming more into focus as we refine our protocol and navigate the process."
The U.S. regulatory push builds on expanding visibility for Vision AI across Latin America. In June, Vargas was featured at Roche's "Macular Spectacular" Ophthalmology Conference in Cartagena, Colombia, where he presented Vision AI as a cost-effective screening tool that can prevent diabetic blindness and improve health access in low-resource settings. He also highlighted a Q4 2024 pilot with Roche and Salud 360 that could scale across the U.S., Canada, and Europe if successful.
Meanwhile, Vision AI has gone live through Grupo Dökka's Fischel and La Bomba pharmacy chains, offering walk-in screenings, real-time AI results, and direct referrals to care providers. The model eliminates the need for onsite ophthalmologists and is gaining traction with pharmacy chains, insurers, and life sciences partners.
Avant and Ainnova's FDA engagement follows an earlier pre-submission meeting in July, where the agency provided clear guidance on study design and compliance. The refined clinical trial protocol, once greenlit, will guide a formal U.S. study aimed at supporting FDA clearance to market Vision AI domestically.
Avant maintains global licensing rights to Ainnova's platform through Ai-nova Acquisition Corp., the JV established to commercialize Ainnova's technology portfolio. U.S. entry is viewed as a major inflection point with significant commercial potential.
Looking ahead, Vision AI could serve as a frontline tool for broader disease detection. Ainnova's future roadmap includes a cloud-connected retinal camera for rural clinics and new modules aimed at identifying Alzheimer's, cardiovascular conditions, and other chronic diseases through retinal or blood biomarkers.
Avant has also signaled plans for a dedicated therapeutic-focused spinout and continues to evaluate a full acquisition of Ainnova Tech under a previously announced non-binding LOI—potentially consolidating all assets and leadership under a single public platform.
CONTINUED... Read this and more news for Avant Technologies at:
Renovaro Inc. (NASDAQ: RENB) secured multiple U.S. patents for its federated AI learning technologies in biomedical research.
"Expanding our IP footprint in federated learning and AI-based data harmonization directly supports our long-term vision: to be the platform of choice for next-generation biomedical research and precision medicine," said David Weinstein, CEO, Renovaro.
These patents support secure, privacy-preserving data integration across hospitals and labs for applications in drug discovery and precision medicine. The move strengthens Renovaro's position in the $20 billion biomedical AI space.
Healthcare Triangle, Inc. (NASDAQ: HCTI) recently signed major contracts with large U.S. hospital systems and expanded its AI-powered EHR services. Its Readeable.AI platform converts unstructured medical documents into usable data for clinicians.
"These strategic wins reflect our ability to deliver enterprise-scale transformation with speed and precision," said Sujatha Ramesh, Chief Operating Officer of Healthcare Triangle." We're driving digital maturity, operational efficiency, and cost-effective care delivery - firmly positioning HCTI as a mission-critical partner, not just a service provider."
The company is focused on making EHR systems smarter, more efficient, and better suited to community health networks.
GE HealthCare Technologies Inc. (NASDAQ: GEHC) launched its Definium Pace Select ET, an AI-powered digital X-ray system for high-volume medical settings.
"This launch reinforces our commitment to provide accessible, efficient, and high-quality care for patients, while alleviating stress from the technologist's workday by minimizing repetitive tasks and automating steps," said Jyoti Gupta, PhD, President and CEO of Women's Health and X-ray at GE HealthCare. "We remain dedicated to advancing our technology through transformative digital and AI-enabled capabilities that will remove barriers to timely and effective diagnostic imaging for any patient in need of X-ray imaging."
The system automates repetitive tasks and improves image consistency to help radiologists work more efficiently. It's designed to relieve staffing pressures while maintaining high imaging standards in busy hospitals.
Spectral AI, Inc. (NASDAQ: MDAI) submitted its DeepView System to the FDA for marketing approval under the De Novo pathway.
"This FDA submission is a major milestone for Spectral AI and the DeepView System, representing a crucial step toward bringing this innovative diagnostic device to market in the United States," said Dr. J. Michael DiMaio, MD, Chairman of the Board at Spectral AI. "It provides clinicians with an immediate, data-driven assessment tool designed to assist clinical decision-making and may significantly improve patient outcomes."
The device uses multispectral imaging and AI to predict how burn wounds will heal, helping doctors make faster and more accurate treatment decisions. It's positioned as a first-of-its-kind diagnostic tool in burn care.
CONTACT:
Equity Insider
info@equity-insider.com
(604) 265-2873
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Logo - https://mma.prnewswire.com/media/2644233/5436444/Equity_Insider_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/ai-just-got-a-green-light-from-the-white-househeres-what-that-means-for-healthcare-stocks-302516506.html
Issued on behalf of Avant Technologies Inc.
Equity Insider News Commentary
VANCOUVER, BC, June 10, 2025 /PRNewswire/ -- Both politicians and leaders in academia are touting the AI revolution empowering the frontline of what's dubbed Smart Healthcare. In a recent write-up in Forbes, Prof. Nicos Savva of the London Business School cited recent speeches from former British Prime Minister Tony Blair, who insists that the UK needs to embrace a future with AI doctors and nurses, or risk being left behind. A new report from Wolters Kluwer has experts calling for more clarity around its use, adoption, and business strategy, because most healthcare organizations aren't currently ready to use GenAI tools. But as implementations increase across the sector, so too are major developments coming from innovators, including Avant Technologies, Inc. (OTCQB: AVAI), Renovaro Inc. (NASDAQ: RENB), Alphabet, Inc. (NASDAQ: GOOG) (NASDAQ: GOOGL), Omada Health, Inc. (NASDAQ: OMDA), and Amazon.com, Inc. (NASDAQ: AMZN).
McKinsey's Global Institute estimates Gen AI could unlock $60–110 billion in annual value across pharma and medical products alone. Statista now projects the global AI healthcare market will soar from $11 billion to $188 billion by 2030.
Avant Technologies, Inc. (OTCQB: AVAI) has just taken a major step forward in its evolution from AI incubator to full-stack healthcare innovator. Today, the company announced it had signed a non-binding letter of intent to acquire 100% of Ainnova Tech, its joint venture partner and the developer of the Vision AI diagnostic platform. Prior to the acquisition, the two companies have been operating jointly through Ai-nova Acquisition Corp (AAC), which holds global licensing rights to Ainnova's technology portfolio and serves as the commercialization engine for Vision AI and all future device deployments.
"We believe bringing the two companies together will offer tremendous value for shareholders, it will simplify the process of advancing our technology to market, and it will deliver value to our customers and partners as we promote our technology portfolio globally," said Vinicio Vargas, CEO at Ainnova and a member of the Board of Directors of AAC. "We feel the joint venture has been a success and both companies have worked well together toward a common goal, so we believe that we can be even more successful and use our resources more effectively as one company to further AI in healthcare."
Under the proposed agreement, Ainnova would roll all of its outstanding equity into the combined public entity — unifying leadership and eliminating structural complexity ahead of a scheduled FDA pre-submission meeting in July.
While final terms of the deal are still being negotiated, both companies say the merger would streamline commercialization and accelerate the rollout of Ainnova's flagship Vision AI technology — a platform already in use across clinical sites in Latin America for the early detection of diabetic retinopathy, cardiovascular disease, and other chronic conditions. The move also signals growing confidence from Avant's leadership as they prepare to bring proprietary hardware into the mix.
In parallel with the merger discussions, Avant and Ainnova are entering the final prototyping stage of a low-cost, automated retinal imaging device — marking a potential turning point in the companies' shared push toward AI-powered early diagnostics.
The new device is designed to operate hands-free and feed imaging data directly into the Vision AI platform, enabling near-instant risk reports without expensive equipment or trained personnel.
The companies say the camera, developed under their joint venture Ai-nova Acquisition Corp. (AAC), is expected to cost a fraction of legacy fundus cameras. By combining affordability with automation, the device could expand screening access across primary care clinics and emerging-market providers that have traditionally been priced out of ophthalmic diagnostics.
"The cost of a fundus camera has always been a barrier to entry in this market," said Vargas. "Our low-cost camera, which is a fraction of the cost of currently available cameras on the market, should allow us to not only enter the market, but to capture a large share of the market."
Also in development are additional platform modules, including a patented dementia detection tool that combines a five-minute blood test with AI-trained algorithms. Although that technology remains in evaluation, the core platform continues to expand its reach and functionality — evolving from a retinal-focused application into a broader engine for predictive healthcare.
"Our purpose is to create the future of early disease detection in an accessible way, so that patients can get a preventive check-up anywhere, at a low cost, and easily," said Vargas in a previous statement. "We want to prevent patients with risk factors from developing other diseases that could have been avoided before they became a real problem. To this end, we are seeking to integrate new technologies into our portfolio within a single platform, both through our R&D efforts and through potential exclusive licenses or acquisitions."
As the camera prototype nears completion, Avant is positioning itself for broader market entry. While a launch date has yet to be announced, the integrated platform is designed to reduce diagnostic friction, speed up referrals, and expand access to early-stage health insights — especially in geographies where affordability, not innovation, remains the primary barrier to care.
CONTINUED... Read this and more news for Avant Technologies at:
Renovaro Inc. (NASDAQ: RENB) recently announced a major expansion to its intellectual property portfolio with a newly approved U.S. patent for its AI-powered drug discovery and diagnostics infrastructure.
"This patent is a strategic milestone for Renovaro," said David Weinstein, CEO of Renovaro. "Together with our previously granted patent, it forms the technological foundation of a scalable, end-to-end platform for AI-powered drug discovery and diagnostics and strengthens our position in the fast-growing market for data-driven therapeutics and clinical insights."
The patent protects methods that harmonize genomic, imaging, clinical, and health record data into a standardized framework for large-scale predictive analytics. These capabilities are built for distributed computing environments, aligning with the biopharma industry's move toward real-time, scalable analytics. The development enhances Renovaro's competitive positioning in data-driven therapeutics and clinical insight markets.
Alphabet, Inc. (NASDAQ: GOOG) (NASDAQ: GOOGL) recently showcased its leadership in AI-driven cancer research at the 2025 ASCO Annual Meeting, where Ruth Porat discussed Alphabet's evolving role in early diagnosis and treatment.
"AI has greater potential than the internet, because it can augment human capabilities," wrote Ruth Porat, President & Chief Investment Officer of Alphabet and Google, quoting Vint Cerf. "It is a partner for all of you, for each of us."
Porat highlighted Google's success with AlphaFold, which has accelerated cancer drug discovery by solving the decades-long problem of protein folding. She also noted the company's AI-assisted pathology tools that cut diagnostic time in half and improve detection of small metastases. From scalable diabetic retinopathy screening to generative AI for clinical workflows, she framed AI as a transformative force in healthcare delivery.
Omada Health, Inc. (NASDAQ: OMDA) entered the public markets with a strong debut, raising $150 million and closing its first trading day 21% above IPO pricing. The company delivers AI-augmented virtual care for chronic conditions like diabetes, hypertension, and obesity, serving more than 679,000 active members.
In May, prior to the IPO, Omada introduced Nutritional Intelligence, a new member experience powered by OmadaSpark—an AI agent that offers personalized, evidence-based nutrition coaching between clinical visits. As demand rises for GLP-1 medications, Omada is positioning its human-plus-AI model as essential to long-term metabolic health.
"We believe there is a clear market need for real-time educational support backed by behavioral science to improve mindsets and behaviors toward food," said Wei-Li Shao, President at Omada Health. "To meet the needs of our customers and members, Omada fine tuned its approach to offer AI-powered tools trained with clinical input and expertise to work alongside human care teams in helping members drive improved health and economic outcomes."
Amazon.com, Inc. (NASDAQ: AMZN) continues to scale its digital health footprint via Amazon Web Services (AWS), which recently brought its HealthLake platform to the EU's Dublin Region. The move enables hospitals and insurers to unify siloed patient data using FHIR standards, while running AI-driven analytics and maintaining full data residency compliance.
"I'm excited about AWS HealthLake launch in EU Region," said Ramon Postulart, CTO at Adapcare. "AWS HealthLake is a key AWS healthcare service helping us modernize interoperability across the 70+ care organizations and 60,000 health professionals we support in the Netherlands. By moving to this service, we're unlocking richer, standardized health data and leveraging the HealthLake fully managed capabilities to build smarter, AI-powered tools for care planning and coordination."
HealthLake now serves as the engine behind personalized care tools in development across Ireland, the Netherlands, and Finland. AWS also hosted its Health Data & AI Day in Dublin to promote cross-border health data innovation and the European Health Data Space initiative.
CONTACT:
Equity Insider
info@equity-insider.com
(604) 265-2873
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Logo - https://mma.prnewswire.com/media/2644233/5362794/Equity_Insider_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/smart-healthcare-is-taking-over-heres-where-the-moneys-headed-302477872.html
